8% by mass or more of fulvestrant based on the total mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable non-aqueous carrier satisfying (A) and (B) And a pharmaceutical composition comprising. (1) It contains 8% by mass or more of ethanol with respect to the total mass of the pharmaceutical composition. (2) It contains at least one polyhydric alcohol selected from propylene glycol and 1,3-butylene glycol in an amount of 3% by mass or more based on the total mass of the pharmaceutical composition. (3) The content of benzyl alcohol is less than 5% by mass relative to the total mass of the pharmaceutical composition. (4) The content of the aqueous solvent is 15 to 50% by mass with respect to the total mass of the pharmaceutical composition. (A) The content rate of benzyl benzoate is less than 1 mass% with respect to the total mass of a pharmaceutical composition. (B) The content rate of a non-aqueous carrier is 40-75 mass% with respect to the total mass of a pharmaceutical composition.医薬組成物の全質量に対して８質量％以上のフルベストラントと、(1)～(4)を満たす水性溶媒と、(A)及び(B)を満たす医薬的に許容される非水性担体と、を含む医薬組成物。(1)医薬組成物の全質量に対して８質量％以上のエタノールを含む。(2)医薬組成物の全質量に対して３質量％以上の、プロピレングリコール及び１，３－ブチレングリコールから選ばれる少なくとも１種の多価アルコールを含む。(3)ベンジルアルコールの含有率が医薬組成物の全質量に対して５質量％未満。(4)水性溶媒の含有率が、医薬組成物の全質量に対して１５～５０質量％。(A)安息香酸ベンジルの含有率が医薬組成物の全質量に対して１質量％未満。(B)非水性担体の含有率が医薬組成物の全質量に対して４０～７５質量％。
